Thailand’s Chulalongkorn University’s Centre of Excellence in Vaccine Research and Development is recruiting 174 volunteers for human trials of its vaccine, known as ChulaCov19, scheduled to start at the end of August.
On its Facebook page, the centre is asking for volunteers to join the human trials. The first phase of the trial involves 24 volunteers, aged from 65 to 75, who do not have any of the underlying diseases, have never been infected with COVID-19 and have not been inoculated against COVID-19.
The second phase involves 150 volunteers, aged from 18 to 55 who must be in good health.
Volunteers who live in or around Bangkok are preferred, because they have to receive the vaccine and undergo health checks at Chulalongkorn Hospital.
Those who meet the initial requirements will be contacted by officials for screening, prior to joining the program. Those who fail the screening will be notified via SMS by July 23rd.
Anyone interested can apply, until July 2nd, by scanning the QR code appearing on the centre’s Facebook post and completing the personal information form at the following link:
According to the centre’s director, Dr. Kiat Ruxrungtham, the first phase is to assess the right dosage and the second is to determine the vaccine’s efficacy and safety.
ChulaCov19, an mRNA vaccine, is the result of a collaboration between the centre and Pennsylvania University in the US. The vaccine can be stored at 2-8oC for as long as three months and can last two weeks in room temperature.